3.01%QQQQ 43.66 3.24%XLF 20.98 4.90%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
LONDON - Drugmaker AstraZeneca PLC said Friday that U.S. regulators have approved a new once-daily version of its Seroquel schizophrenia drug.
Seroquel is the company's second-biggest-selling drug, with global sales of $3.4 billion last year, and analysts said approval by the U.S. Food and Drug Administration of Seroquel XR was important to extend the life cycle of the family of drugs.
The new version of the drug is under patent until 2017, while its original immediate-release formulation of the drug is facing patent challenges in the United States.
Dresdner Kleinwort said that it expects AstraZeneca to achieve a successful patient switch to the new version, but does not expect a further boost to the drug's market share.
The company has been attempting to boost its range of drugs, but suffered two recent high-profile failures of two new drugs for stroke and heart disease, which followed earlier setbacks.
AstraZeneca shares rose 0.11 percent to 2,748 pence ($54.31) Friday.
Gold headed back to revisit Tuesday's low of $790 and then recovered once again before the close of futures trading, to climb back to just a...
Stephenie Meyer, who wrote 'Twilight', will not continue writing ...
IN THE HEADLINES McCain caps GOP convention vowing 'change is coming' to Washing...
|
Professional Website Design For Corporate - Get a Free Quote Today
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
